Navigation Links
New Studies Demonstrate Clinical Utility and Validity of CancerType ID® Molecular Classifier
Date:3/22/2012

tts General Hospital (MGH).

The same researchers also evaluated the use of CancerTYPE ID to predict the site of origin for primary and metastatic tumors with neuroendocrine differentiation (USCAP 2012 Abstract # 604). Findings from this analysis indicated CancerTYPE ID may address an unmet medical need as a molecular correlate for sub-typing neuroendocrine tumors. The ability to subtype neuroendocrine tumors, among the most difficult to determine, has important implications for grading, staging and disease management.

"The 92-gene classifier demonstrated excellent accuracy for subtyping tumors with neuroendocrine differentiation," said Mark Erlander, PhD, Chief Scientific Officer of bioTheranostics. "While these results were part of a larger parent study designed to characterize performance of the classifier in a broad range of tumor histologies, these findings show promise for use of the 92-gene assay in classifying neuroendocrine tumors of uncertain primary site."

"In these recent studies, CancerTYPE ID's accuracy was also noted in both metastatic as well as poorly differentiated primary tumors, and its diagnostic value was maintained even in situations where there was limited tissue," said Richard Ding, Chief Executive Officer of bioTheranostics. "We believe this is an important step in discovering where a molecular classifier, such as CancerTYPE ID, fits in the diagnostic picture as an accurate, objective and time-saving adjunctive pathology asset. We appreciate the independent and growing support from pathologists in utilizing CancerTYPE ID as a standardized diagnostic aid in their workup of metastatic cancers."

About bioTheranostics

Advancing Molecular Diagnostics in Oncology

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to
'/>"/>

SOURCE bioTheranostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
10. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
11. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015 VWR (NASDAQ: ... and solutions, announces the redesign of its global website, ... When visiting the new site, guests will enjoy enhanced ... and vivid images.  Each country site now includes: ... Z product menu; and , the ability to search ...
(Date:8/3/2015)... -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced ... Investor Conference Call and webcast at 4:30 p.m., Eastern time, ... cover an update on Merrimack,s progress as well as ... release detailing the information to be discussed on the ... 10. Investors and the general public are invited to ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. , Aug. ... naldemedine met its primary and secondary endpoints in a ... opioid-induced constipation (OIC) in adult patients with chronic non-cancer ... receptor antagonist (PAMORA). This is the third Phase III ... secondary endpoints. Study results showed that a ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... (NYSE: CBM ) reports fourth quarter and full year ... Highlights Reported sales increased by 8.2%, ... to fourth quarter 2009. Adjusted EBITDA was $14.5 million in ... million of EBITDA in the fourth quarter of 2009. Debt, ...
... the Obama administration embarks on improving the efficiency of ... for Medicare & Medicaid Services, (CMS) supervision of the ... hard pressed to find a government operation more outdated, ... In fact, recent audits by the government,s own contractors ...
Cached Medicine Technology:Cambrex Reports Fourth Quarter and Full Year 2010 Results 2Cambrex Reports Fourth Quarter and Full Year 2010 Results 3Cambrex Reports Fourth Quarter and Full Year 2010 Results 4Cambrex Reports Fourth Quarter and Full Year 2010 Results 5Cambrex Reports Fourth Quarter and Full Year 2010 Results 6Cambrex Reports Fourth Quarter and Full Year 2010 Results 7Cambrex Reports Fourth Quarter and Full Year 2010 Results 8Cambrex Reports Fourth Quarter and Full Year 2010 Results 9Mobility Matters: Frustrated Mobility Providers Ask White House to Address Gross Mismanagement of Mobility Benefit 2Mobility Matters: Frustrated Mobility Providers Ask White House to Address Gross Mismanagement of Mobility Benefit 3Mobility Matters: Frustrated Mobility Providers Ask White House to Address Gross Mismanagement of Mobility Benefit 4Mobility Matters: Frustrated Mobility Providers Ask White House to Address Gross Mismanagement of Mobility Benefit 5
(Date:8/3/2015)... ... August 03, 2015 , ... Kantor & Kantor, LLP announced ... firm’s client Rebecca Hamsher, deciding that in accordance with ERISA ( Employee Retirement ... residential treatment for bulimia, depression and other mental health problems. , According to ...
(Date:8/3/2015)... ... 03, 2015 , ... Pitt Researchers to Monitor Resistance to ... School of Medicine are leading a five-year, $5 million initiative to monitor drug ... A cooperative agreement awarded by the U.S. Agency for International Development (USAID), will ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can ... costs. , Annually, more than 8.6 million adverse drug events are reported ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, the ... and consumer health products, today welcomed the announcement by OPKO Health that the ... for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in ... patients in need. Most people know that general health emergencies, such as broken arms ... amount of people know where to turn to during a dental emergency. This is ...
Breaking Medicine News(10 mins):Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3
... 14 , News Facts: -- A study published ... Association ( http://jama.ama-assn.org/cgi/content/short/299/24/2884 ) ... in medical devices" used in hospitals. ... RFID readers in favor of an uncommonly ...
... DALLAS, July 14 Colon and rectal ... and are second only to,lung cancer in ... many of,these lives, according to Boyd Lyles, ... ( http://www.USPreventiveMedicine.com ), an,organization specializing in prevention., ...
... and soap going down the plughole: that,s how the British ... , Women in Britain are particularly guilty of wasting shower ... the Royal Society of Chemistry . , But men ... don,t care about what they wash down the drain. The ...
... VIRGINIA BEACH, Va., July 14 The AMERIGROUP ... Houston has been honored with,its "Champion for Children" ... AMERIGROUP Foundation,s national program,recognizing outstanding public advocacy efforts ... and well-being of children nationwide., "Our goal ...
... Increase Annual Sales by 14.4 Million RMB, ... Biotech Inc. (the "Company") (OTC Bulletin Board: CKGT), ... a,variety of cactus-based consumer products in China, announced ... Cattle Feed and Cactus Fish,Feed. It is expected ...
... Delicious, Antioxidant-Rich Fruit and ... Trends for 2008, BOULDER, Colo., July 14 ... is launching GoodBelly(TM) -- a new nutritious,and delicious ... http://www.goodbelly.com ). Probiotics -- which are,healthy bacteria, that ...
Cached Medicine News:Health News:Study Published in JAMA on RFID Interference Ignores Real-World Use Cases, According to SkyeTek 2Health News:Study Published in JAMA on RFID Interference Ignores Real-World Use Cases, According to SkyeTek 3Health News:Study Published in JAMA on RFID Interference Ignores Real-World Use Cases, According to SkyeTek 4Health News:U.S. Preventive Medicine: Knowing Risk Factors & Early Detection are Best Strategies for Colon Cancer Prevention 2Health News:U.S. Preventive Medicine: Knowing Risk Factors & Early Detection are Best Strategies for Colon Cancer Prevention 3Health News:British showers most wasteful and inconsiderate in Western Europe 2Health News:Texas State Rep. John Davis Honored as 'Champion for Children' by The AMERIGROUP Foundation 2Health News:China Kangtai Cactus Biotech Inc. Launches Cactus Cattle Feed and Cactus Fish Feed 2Health News:Introducing GoodBelly(TM) the New Probiotic Fruit Drink Line 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: